Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
Overweight and obese women who had surgery plus radiation therapy to treat breast cancer, and who had 12 or more lymph nodes removed, were more likely to develop lymphedema than women of normal weight, an analysis showed.
A study of about 7,000 women treated with tamoxifen for early-stage, ER+ breast cancer showed lower recurrence and mortality rates for those who took the medication for 10 years instead of 5 years. This research, which has not yet been published, reinforces the findings of the international ATLAS trial.
In a recent study, researchers found that most women diagnosed with breast cancer do not meet national physical activity guidelines in the 10 years after diagnosis.
New findings show women treated for breast cancer who report trouble with memory and problem solving skills do perform worse on tests of cognitive function than women who were never diagnosed. Cognitive function refers to a person’s attention, memory, and ability to reason, learn and understand.
New research shows triple-negative breast cancer tumors may have high levels of a certain protein in common. Identification of this protein may lead to better understanding of how the cancer grows, and how to more effectively treat it in the future.
Through a subanalysis of data from EMILIA, the clinical trial that led to FDA approval of T-DM1, researchers found that the amount of HER2 messenger RNA (mRNA) present in HER2 positive, metastatic tumors may predict how well that breast cancer will respond to the medicine. Messenger RNA is a type of molecule that carries genetic information to help make proteins. The more mRNA measured on tumor cells, the more HER2 proteins present, and the more responsive those cells will be to T-DM1.
Young women whose surgery-only breast cancer treatment is delayed longer than 6 weeks have decreased survival rates compared with women who are treated sooner.
NEW YORK (Reuters Health) - Differences in the health and tumor characteristics of white and black women with breast cancer at the time of their diagnoses may be largely to blame for the disparity in survival between the two groups, a new study suggests.
A genetic analysis of triple-negative tumors cataloged in The Cancer Genome Atlas found that triple-negative breast cancers can be broken down into two main groups: those that are basal-like, and those that are non-basal-like.
How breast cancer responds to early chemotherapy may someday help doctors decide the need for radiation therapy based on individuals’ risk of recurrence, a study showed.